Association of HNF1B-rs4794758 and LMTK2-rs7791463 Gene Variants with Prostate Neoplasia Risk: Case-control and Bioinformatics Studies

Journal of Cell and Molecular Research

مقاله 5، دوره 16، شماره 1 - شماره پیاپی 31، دی 2024، صفحه 47-55   

نوع مقاله: Research Articles

شناسه دیجیتال (DOI): 10.22067/jcmr.2024.87455.1089

نویسندگان

Fereshteh Jozaghkar¹؛ Abasalt Hosseinzadeh Colagar^{* 1}؛ Mohammadreza Hosseinzadeh¹؛ Faramarz Mehrnejad²؛ Emadoddin Moudi³

¹Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran

²Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran

³Clinical Research Development Unit of Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Mazandaran, Iran

چکیده

Prostate neoplasms, such as prostate cancer and benign prostatic hyperplasia, are complex and heterogeneous diseases that are caused by environmental, metabolic, and genetic factors. Various reports showed the relationship of several genes, including the HNF1B and LMTK2 genes, in the occurrence of prostate cancer. This study investigated the association of HNF1B-rs4794758 and LMTK2-rs7791463 polymorphisms with prostate cancer and benign prostatic hyperplasia in a case-control study, followed by bioinformatics analysis. For this purpose, blood samples were collected from 70 healthy men, 58 men with benign prostatic hyperplasia (positive digital rectal examination or DRE and PSA levels below 4 ng/mL), and 70 men with prostate cancer (positive DRE, PSA levels above 4 ng/mL, and diagnoses confirmed by pathological findings). These men were referred to Shahid Beheshti Hospital in Babol. After genomic DNA extraction, the genotype was determined using PCR-RFLP. A genotypic and allelic analysis revealed that the rs4794758 polymorphism with AA genotype (OR: 4.808, 95%CI: 1.260-18.348, P= 0.022) had a significant difference between the prostate cancer group and the benign prostatic hyperplasia group compared to the control group. Allele A of this polymorphism was also significantly associated with prostate cancer (OR: 1.705, 95%CI: 1.055-2.755, P= 0.030). However, there was no correlation between different genotypes of the rs7791463 polymorphism with prostate cancer and benign prostatic hyperplasia. Bioinformatics analysis by some online servers and software showed that the rs4794758 polymorphism possibly changes the hnRNA splicing pattern. So, this polymorphism could probably provide a locus for the TBP transcription factor. In addition, the rs7791463 polymorphism potentially alters the hnRNA splicing pattern and changes the reading frame. Based on the data, HNF1B-rs4794758 polymorphism is associated with prostate cancer susceptibility, which can be considered a molecular risk factor in future studies.

کلیدواژه‌ها

Benign prostate hyperplasia؛ Genetic polymorphism؛ HNF1B gene؛ LMTK2 gene؛ Prostate cancer

مراجع

Ross-Adams H., Ball S., Lawrenson K., Halim S., Russell R., Wells C. and et al. (2016). HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget 7(46):74734-74746.

Berndt S. I., Sampson J., Yeager M., Jacobs K. B., Wang Z., Hutchinson, A. and et al. (2011). Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Human Molecular Genetics 20(16), 3322-3329.

Colagar A.H, Arjmand M., Heydari M. and Jorsaraei GhA. (2023). COL12A1-rs970547, mutant allele advantage by being protective against recurrent spontaneous abortion. Journal of Genetic Resources 9(1): 59-68.

Conti A., Majorini M. T., Fontanella E., Bardelli A., Giacca M., Delia D. and et al. (2017). Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members. Cancer Letters 389: 59-69.

Denmeade S. R. and Isaacs J. T. (2004). Development of prostate cancer treatment: the good news. The Prostate 58(3): 211-224.

Dhanasekaran S. M., Barrette T. R., Ghosh D., Shah R., Varambally S., Kurachi K., and et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849): 822–826.

Eeles R. A., Kote-Jarai Z., Giles G. G., Al Olama A. A., Guy M., Jugurnauth S. K. and et al. (2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics 40(3): 316-321.

Hamid T., MalikM. T., Millar R. P. and Kakar S. S. (2008). Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LβT2 mouse pituitary gonadotroph tumor cell line. International Journal of Oncology 33(5): 1055-1064.

Harries L. W., Perry J. R., McCullagh P. and Crundwell M. (2010). Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 10(1):315.

Helfand B. T. and Catalona W. J. (2014). The Epidemiology and Clinical Implications of Genetic Variation in Prostate Cancer. Urologic Clinics of North America 41(2): 277-297.

Igarashi P., Shao X., Mcnally B. T. and Hiesberger T. (2005). Roles of HNF-1β in kidney development and congenital cystic diseases. Kidney International 68(5): 1944-1947.

Inoue T., Kon T., Ohkura R., Yamakawa H., Ohara O., Yokota J. and Sutoh K. (2008). BREK/LMTK2 is a myosin VI binding protein involved in endosomal membrane trafficking. Genes to Cells 13(5): 483-495.

Jemal A., Bray F., Center M. M., Ferlay J., Ward E. and Forman D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians 61(2): 69-90.

Kim E. H., Larson J. A. and Andriole G. L. (2016). Management of benign prostatic hyperplasia. Annual Review of Medicine 67: 137-151.

Kumar V. L. and Majumder P. K. (1995). Prostate gland: structure, functions and regulation. International Urology and Nephrology 27(3): 231-243.

Langan R. C. (2019). Benign prostatic hyperplasia. Primary Care: Clinics in Office Practice 46(2): 223-232.

Leitzmann M. F. and Rohrmann S. (2012). Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clinical Epidemiology 4: 1–11.

Levin A. M., Machiela M. J., Zuhlke K. A., Ray A. M., Cooney K. A. and Douglas J. A. (2008). Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Research 68(16): 6492-6495.

Lloyd T., Hounsome L., Mehay A., Mee S., Verne J. and Cooper A. (2015). Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010. BMC medicine 13: 171.

Manser C., Vagnoni A., Guillot F., Davies J. and Miller C. C. (2012). Cdk5/p35 phosphorylates lemur tyrosine kinase‐2 to regulate protein phosphatase‐1C phosphorylation and activity. Journal of neurochemistry 121(3):343-348.

Naghiyan Fesharaki S. and Sisakhtnezhad S. (2022). In silico analysis of possible novel RNA interactions and deleterious single nucleotide polymorphisms related to MSX2, SHH, SMAD7 and TFAP2 genes involved in odontogenesis. Journal of Genetic Resources 8(2): 165-177.

Puri C., Chibalina M. V., Arden S. D., Kruppa A. J., Kendrick-Jones J. and Buss F. (2010). Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 29(2): 188-200.

Shah K. and Bradbury N. A. (2015). Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy. Oncotarget 6(16): 14233.

Solovieff N., Cotsapas C., Lee P. H., Purcell S. M. and Smoller J. W. (2013). Pleiotropy in complex traits: challenges and strategies. Nature Reviews Genetics 14(7): 483-495.

Wang L., Lu B., He M., Wang Y., Wang Z. and Du L. (2022). Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in Public Health 10: 811044.

Yeager M., Xiao N., Hayes R.B., Bouffard P., Desany B., Burdett L. and et al. (2008). Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Human Genetics 124, 161-170.